Abstract:There is a large, unmet medical need to treat chronic obstructive pulmonary disease, asthma, idiopathic pulmonary fibrosis and other respiratory diseases. New modalities are being developed, including gene therapy which treats the disease at the DNA/RNA level. Despite recent innovations in non-viral gene therapy delivery for chronic respiratory diseases, unwanted or adverse interactions with immune cells, particularly macrophages, can limit drug efficacy. This review will examine the relationship between the design and fabrication of non-viral nucleic acid nanoparticle (NP) delivery systems and their ability to trigger unwanted immunogenic responses in lung tissues. NP formulated with peptides, lipids, synthetic and natural polymers provide a robust means of delivering the genetic cargos to the desired cells. However NP, or their components, may trigger local responses such as cell damage, edema, inflammation, and complement activation. These effects may be acute short-term reactions or chronic long-term effects like fibrosis, increased susceptibility to diseases, autoimmune disorders, and even cancer. This review examines the relationship between physicochemical properties, i.e. shape, charge, hydrophobicity, composition and stiffness, and interactions of NP with pulmonary immune cells. Inhalation is the ideal route of administration for direct delivery but inhaled NP encounter innate immune cells, such as alveolar macrophages (AM) and dendritic cells (DC), that perceive them as harmful foreign material, interfere with gene delivery to target cells, and can induce undesirable side effects. Recommendations for fabrication and formulation of gene therapies to avoid adverse immunological responses are given. These include fine tuning physicochemical properties, functionalization of the surface of NP to actively target diseased pulmonary cells and employing biomimetics to increase immunotolerance.

Engineering Cells or Cellular Outer Membranes As Multifaceted Vehicles for Reinforcing Nanomedicine-Based Pulmonary Disease Treatment

Neutrophil‐Based Delivery Systems for Nanotherapeutics

Cell-derived Membrane Biomimetic Nanocarriers for Targeted Therapy of Pulmonary Disease

Nanomedicine in cardiology: Precision drug delivery for enhanced patient outcomes

Bioengineered Abiotic Nanomaterials Through Cell Membrane-Camouflaging: Advancements and Challenges in Lung Cancer

Multifaceted Applications of Nanomaterials in Cell Engineering and Therapy

Recent Advancement in Inhaled Nano-drug Delivery for Pulmonary, Nasal, and Nose-to-brain Diseases

Cell-membrane engineering strategies for clinic-guided design of nanomedicine

Moving beyond traditional therapies: the role of nanomedicines in lung cancer

"Nano-in-Micro" Structured Dry Powder Inhalers for pulmonary delivery: advances and challenges

Advances, challenge and prospects in cell-mediated nanodrug delivery for cancer therapy: a review

Nanoparticle-Based Drug Delivery Systems in Inhaled Therapy: Improving Respiratory Medicine

Nanotechnology Reinforced Neutrophil-Based Therapeutic Strategies for Inflammatory Diseases Therapy

Advanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug Delivery

Nanoapproaches to Modifying Epigenetics of Epithelial Mesenchymal Transition for Treatment of Pulmonary Fibrosis

Progress in the Application of Nano- and Micro-based Drug Delivery Systems in Pulmonary Drug Delivery

Combination of Nanomaterials in Cell-Based Drug Delivery Systems for Cancer Treatment

Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release

Nanoengineered Polymers and Other Organic Materials in Lung Cancer Treatment: Bridging the Gap Between Research and Clinical Applications

Nanocrystals based pulmonary inhalation delivery system: advance and challenge

Adverse immunological responses against non-viral nanoparticle (NP) delivery systems in the lung